RxDoctor Payments Data

Chandrasekar Vaidyanathan, MD

Internal Medicine · Batavia, OHNPI 1659373553

Payments from drug & device makers

$522in general payments, 2019–2025

Across 22 payments — averaging $23.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$181
  • Novartis$97
  • AbbVie$55
  • Astellas Pharma US Inc$47
  • GSK$27
  • Merck$24
  • plus $92 from 6 others

What the payments were for

  • Food & beverage$522100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$522 in reported general payments places this provider in the 65th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$145,783
Medicare patients
541
Services billed
1,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$102,077
JardianceEmpagliflozin74$59,467
JanuviaSitagliptin Phosphate56$57,281
Trelegy ElliptaFluticasone/Umeclidin/Vilanter51$33,965
TrulicityDulaglutide32$32,941
XareltoRivaroxaban36$31,756
OzempicSemaglutide27$28,933
Spiriva HandihalerTiotropium Bromide20$17,959
Lantus SolostarInsulin Glargine,hum.Rec.Anlog109$14,206
TradjentaLinagliptin13$13,785
Breo ElliptaFluticasone/Vilanterol17$7,447
SymbicortBudesonide/Formoterol Fumarate23$7,226
Albuterol Sulfate HfaAlbuterol Sulfate163$4,741
Novolog FlexpenInsulin Aspart23$3,953
Atorvastatin Calcium457$3,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$14$73,25287 claims
MerckJanuvia$24$57,28156 claims
GSKTrelegy Ellipta, Breo Ellipta$27$41,41268 claims
Lilly USA, LLCTrulicity$14$32,94132 claims
Johnson & JohnsonXarelto$14$31,75636 claims
Novo NordiskOzempic$20$28,93327 claims
AbbVieSynthroid$55$1,32137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Batavia

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →